Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Preferred Stock Liabilities: 2013-2014

Historic Preferred Stock Liabilities for Zevra Therapeutics (ZVRA) over the last 2 years, with Dec 2014 value amounting to $24.2 million.

  • Zevra Therapeutics' Preferred Stock Liabilities was N/A to $24.2 million in Q4 2014 from the same period last year, while for Dec 2014 it was $24.2 million, marking a year-over-year change of. This contributed to the annual value of $24.2 million for FY2014, which is 30.51% up from last year.
  • Per Zevra Therapeutics' latest filing, its Preferred Stock Liabilities stood at $24.2 million for FY2014, which was up 30.51% from $18.5 million recorded in FY2013.
  • In the past 5 years, Zevra Therapeutics' Preferred Stock Liabilities ranged from a high of $24.2 million in FY2014 and a low of $18.5 million during FY2013.
  • Moreover, its 2-year median value for Preferred Stock Liabilities was $21.4 million (2013), whereas its average is $21.4 million.
  • Data for Zevra Therapeutics' Preferred Stock Liabilities shows a peak YoY surged of 30.51% (in 2014) over the last 5 years.
  • Zevra Therapeutics' Preferred Stock Liabilities (Yearly) stood at $18.5 million in 2013, then soared by 30.51% to $24.2 million in 2014.